Puma Biotechnology (NASDAQ:PBYI - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Wednesday.
Separately, HC Wainwright dropped their target price on shares of Puma Biotechnology from $8.00 to $7.00 and set a "buy" rating for the company in a report on Friday, March 1st.
Get Our Latest Stock Analysis on PBYI
Puma Biotechnology Stock Performance
NASDAQ:PBYI traded down $0.30 during mid-day trading on Wednesday, reaching $5.53. The stock had a trading volume of 378,661 shares, compared to its average volume of 601,923. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.50 and a current ratio of 1.57. The firm has a market capitalization of $266.36 million, a price-to-earnings ratio of 12.01, a PEG ratio of 3.20 and a beta of 1.28. Puma Biotechnology has a twelve month low of $2.13 and a twelve month high of $7.73. The business has a 50 day simple moving average of $5.67 and a 200 day simple moving average of $4.37.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.07). Puma Biotechnology had a net margin of 9.16% and a return on equity of 58.21%. The company had revenue of $72.20 million during the quarter, compared to analysts' expectations of $73.22 million. On average, analysts expect that Puma Biotechnology will post 0.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Puma Biotechnology by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 3,802,081 shares of the biopharmaceutical company's stock worth $16,463,000 after purchasing an additional 29,688 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Puma Biotechnology by 37.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 115,955 shares of the biopharmaceutical company's stock worth $502,000 after acquiring an additional 31,811 shares during the last quarter. Great Point Partners LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth approximately $4,734,000. Balyasny Asset Management L.P. acquired a new stake in Puma Biotechnology during the fourth quarter worth approximately $354,000. Finally, Sei Investments Co. boosted its position in Puma Biotechnology by 2.2% during the fourth quarter. Sei Investments Co. now owns 291,868 shares of the biopharmaceutical company's stock worth $1,264,000 after acquiring an additional 6,211 shares during the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.
About Puma Biotechnology
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Read More
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
